BEAM THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.38 USD | -1.02% |
|
-10.54% | -21.45% |
| 04-04 | Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing | MT |
| 04-04 | Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing | MT |
| Sales 2024 * | 63.42M 5.07B | Sales 2025 * | 64.3M 5.14B | Capitalization | 1.7B 136B |
|---|---|---|---|---|---|
| Net income 2024 * | -452M -36.16B | Net income 2025 * | -447M -35.76B | EV / Sales 2024 * | 14.6 x |
| Net cash position 2024 * | 770M 61.61B | Net cash position 2025 * | 358M 28.66B | EV / Sales 2025 * | 20.8 x |
| P/E ratio 2024 * |
-3.93
x | P/E ratio 2025 * |
-4.2
x | Employees | 436 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Beam Therapeutics Inc.
More recommendations
More press releases
More news
| 1 day | -1.02% | ||
| 1 week | -10.54% | ||
| Current month | -35.29% | ||
| 1 month | -35.29% | ||
| 3 months | -11.98% | ||
| 6 months | +14.82% | ||
| Current year | -21.45% |
1 week
20.84
25.47
1 month
20.8432.99
Current year
20.8449.50
1 year
16.9549.50
3 years
16.95138.52
5 years
13.00138.52
10 years
13.00138.52
| Managers | Title | Age | Since |
|---|---|---|---|
John Evans
CEO | Chief Executive Officer | 46 | 31/12/16 |
| President | 55 | 31/01/18 | |
| Director of Finance/CFO | 47 | 31/07/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Graham Cooper
BRD | Director/Board Member | 54 | 09/10/19 |
John Maraganore
BRD | Director/Board Member | 60 | 04/11/21 |
Mark Fishman
BRD | Director/Board Member | 72 | 30/04/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 8.03% | 2 M€ | -25.75% | ||
| 4.10% | 1 M€ | 0.00% | - | |
| 4.00% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 21.38 | -1.02% | 1,242,944 |
| 25/04/24 | 21.6 | -5.01% | 1,742,568 |
| 24/04/24 | 22.74 | -3.11% | 1,110,291 |
| 23/04/24 | 23.47 | -2.61% | 1,400,065 |
| 22/04/24 | 24.1 | +0.84% | 2,434,712 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Calendar
06/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
21.38
USD
Average target price
49.54
USD
Spread / Average Target
+131.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.45% | 1.7B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- BEAM Stock
